Article
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
The Journal of infectious diseases - 1 Mar 2014
Tong Xiao, Le Pogam Sophie, Li Lewyn, Haines Kristin, Piso Katherine, Baronas Victoria, Yan Jun-Mei, So Sung-Sau, Klumpp Klaus, Nájera Isabel
Abstract excerpt
BACKGROUND: Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation. METHODS: Serum HCV RNA from patients who experienced viral breakthrough, partial response, or nonresponse in 2 clinical trials in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and clonal sequence analysis as well...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.